The Uk Prescription Medicines Code of Practice Authority says it may increase its fees in order to become self-supporting; the Authority is currently subsidized by the Association of the British Pharmaceutical Industry.
In its new review of Code case reports, the Authority also reveals that it proposes to name the respondent companies and products involved in cases, even if no breach of the Code is found. "Outside observers find it difficult to understand why names are given only when a breach is found, and it is a bar to the openness which is needed for a successful self-regulatory system," it says. However, whether this can be done depends on whether the ABPI is prepared to accept it. The Authority is also proposing to move publication of the Review from quarterly to twice-yearly; it asks for comments on this plan.
The following Code breaches were dealt with in December 1994-February 1995:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze